Budget impact of Onvuzosiran
1 evidence topic · 12 sources
Summary
Onvuzosiran is investigational, and its sponsor states that it has “no products approved for commercial sale”. STOP-HAE topline data are expected by the end of 2027, and the sponsor anticipates a potential New Drug Application submission in 2028 if the data are positive. The sponsor is developing onvuzosiran as a subcutaneous treatment given at Q6M and Q3M intervals. No price has been published, and no budget impact model of onvuzosiran was identified. The published inputs a plan would use are listed below with the year of each source.
- US prevalence: the 2018 ICER evidence report projected a US prevalence of 6,690 individuals with HAE type 1 or 2. A 2025 claims analysis estimated 9559, 9341, and 8694 people diagnosed with any type of HAE in 2018, 2019, and 2020 (2.67, 2.61, and 2.43 per 100,000), and 7602, 7275, and 6595 by expert physician analysis. A 2021 patient survey states that HAE caused by C1 inhibitor deficiency affects fewer than 8000 people in the United States. A 2026 systematic literature review reported a pooled diagnosed annual prevalence of 1.43 per 100,000 in North America. The sponsor cites a frequency of approximately 1 in 50,000 people worldwide (2026).
- Fraction eligible for prophylaxis: the 2018 ICER report assumed, from expert opinion, that one-third of patients were eligible for prophylaxis, approximately 2,230 patients, with 446 patients initiating treatment each year. In the 2021 survey, 462 of 737 participants (62.7%) received prophylaxis. A 2026 claims analysis states that approximately 70% of US patients with HAE are treated with long-term prophylaxis.
- Current prophylaxis mix: in the 2026 claims analysis of 328 patients, the first long-term prophylactic agent was lanadelumab in 138 (42%), subcutaneous C1 esterase inhibitor (Haegarda) in 97 (30%), intravenous C1 esterase inhibitor (Cinryze) in 54 (17%), and berotralstat in 39 (12%). The 2018 ICER budget impact analysis assumed a displaced mix of 49% Haegarda, 49% Cinryze, and 2% no long-term prophylaxis. Neither mix includes garadacimab or donidalorsen.
- Annual comparator costs: 2025 Missouri Medicaid drug fact blasts list estimated annual wholesale acquisition costs (WAC) of $747,006 for donidalorsen every 4 weeks ($373,503 every 8 weeks), $685,200 for garadacimab ($742,300 in the first year of therapy), $685,171 for lanadelumab, $665,224 for Cinryze, $604,152 for Haegarda, and $579,885 for berotralstat. A 2026 Colorado WAC disclosure lists berotralstat 150 mg at $48,487.92 per carton of 28 capsules. The 2018 ICER analysis used an annual lanadelumab WAC of $565,557 and a net price of $423,344. Medicare Part D data for 2024 list 512 beneficiaries for lanadelumab, 221 for berotralstat, 187 for Haegarda, and 46 for Cinryze. Federal Supply Schedule and Big Four prices are listed for November 2026, and Medicare Part B payment limits for October 1, 2026 through December 31, 2026.
- Cost offsets: in the 2026 claims analysis, mean annualized HAE-related healthcare costs per patient were $165,348 before and $515,333 after starting long-term prophylaxis, including mean long-term prophylaxis pharmacy costs of $395,845 per patient per year and a reduction in emergency room and inpatient costs of $8344 per patient per year.
- Framework and threshold: the 2018 ICER framework defines potential budget impact as the differential health care cost of the new therapy, including drug costs, minus offsets from averted health care events, undiscounted over a five-year time horizon. Its threshold for 2018-19 was approximately $991 million per year for new drugs. Lanadelumab reached 13% of that threshold at WAC, with an average annual per-patient difference of $96,145 at WAC and -$45,729 at net price against the 49%/49%/2% mix.
The 2018 ICER inputs (prevalence, eligible fraction, displaced mix, lanadelumab price, and threshold) were derived when Cinryze, Haegarda, and lanadelumab were the three drugs approved for long-term prophylaxis of HAE-1/2.